Cutaneous Fibrosis Treatment Market

Cutaneous Fibrosis Treatment Market Outlook (2024 to 2034)

The global cutaneous fibrosis treatment market is projected to be worth US$ 702.2 million in 2024. The industry is anticipated to rise at a CAGR of 5.9% through 2034 and is expected to surpass US$ 1,243.6 million by 2034. The rise in the number of patients afflicted by cutaneous fibrosis-related problems like keloid and scleroderma is ensuring the market’s progress.

Key Market Growth Drivers

• Treatment of cutaneous fibrosis-related problems is still an evolving field. Extensive research is being conducted to understand the nature of cutaneous fibrosis and develop better treatments. The development of newer drugs is also underway with the help of research and development.
• The number of people getting involved in accidents is increasing. Whether road accidents, aided by the increasing number of vehicles on the street, or accidents at home or work, the number of people being admitted to hospitals with physical wounds is on the rise. The formation of scars due to wound repair acts as a genesis for the development of cutaneous fibrosis-related problems.
• Rise in the number of people afflicted with fibrotic diseases is seeing more need for cutaneous fibrosis treatment. Various diseases, like keloid and chronic GVHD are leading to scar formation in patients. The desire to get rid of these scars is fueling patients to seek cutaneous fibrosis treatment.
• Scleroderma is emerging as a prominent problem, especially in the older population. The disease adversely affects the skin. Thus, scleroderma patients comprise a significant consumer base for cutaneous fibrosis treatment.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 702.2 million
Forecasted Market Value (2034F)	US$ 1,243.6 million
Global Market Growth Rate (2024 to 2034)	5.9% CAGR
Immunotherapy Segment Growth Rate (2024 to 2034)	5.1%
Scleroderma Segment Growth Rate (2024 to 2034)	5.9%
North America Market Share (2024)	35.5%
Latin America Market Share (2024)	6.6%
Key Companies Profiled	Novartis AG Pfizer Sanofi F. Hoffmann La Roche (Genetech, Inc.) Boehringer Ingelheim International GmbH Jubilant Cadista Horizon Pharma USA, Inc. Bristol-Myers Squibb Company Teva Pharmaceuticals Amgen Johnson & Johnson Services

Which Factors Have Driven the Global Surge in Cutaneous Fibrosis Treatment Demand?

“Growing Consciousness About the Effectiveness of Diagnostic Treatments is Helping the Demand for Cutaneous Fibrosis Treatment”

The booming healthcare sector, especially in developing countries, has led to diagnostic treatment receiving a more positive outlook among people. Thus, people are more open to diagnostic treatments such as cutaneous fibrosis. Increasing awareness of diseases like keloid and scleroderma among people in developed and developing regions also leads to more people seeking cutaneous fibrosis treatment. The cutaneous fibrosis treatment market outlook remains lucrative with the introduction of new drugs and other forms of treatment, allowing players to expand into untapped regions.

“Growing Number of Needing Radiation Therapies Leading to More Problems with Cutaneous Fibrosis”

The number of people affected by cancer globally is rising. Radiation therapy is one way in which cancer is treated. However, complications regarding fibrosis emerge in several patients undergoing radiation therapy. There has been a growing drive to have cancer-affected people lead normal lives. As a result, cutaneous fibrosis treatment is gaining adoption among people undergoing radiation therapy.

Which Factors Present Challenges to the Expansion of the Cutaneous Fibrosis Treatment Market?

“Lack of Standardized Treatment Procedures, Lack of Awareness Regarding the Treatment, and Limited Treatment Options Hinder the Growth of the Market”

A standardized treatment procedure relating to cutaneous fibrosis has not been developed. Instead, various diseases related to cutaneous fibrosis have varied methods of treatment. However, the lack of centralization of treatment options means many people remain unaware of the treatment.

The unawareness stretches to cutaneous fibrosis, as awareness of diseases like keloid and GvHD-associated cutaneous fibrosis is low. While concentrated efforts are being made to develop novel drugs and treatments, the number of treatment options for cutaneous fibrosis is still lacking, posing a challenge to the growth of the cutaneous fibrosis treatment market.

Country-wise Insights

North America is the dominant region in the market. For 2024, the market value in North America is pegged to be US$ 249.0 million, with a market share of 35.5%. From 2024 to 2034, the market is expected to register a healthy CAGR of 6.1% in North America. During the forecast period, the market is expected to have jumped to US$ 452.0 million, with a share of 36.4% in North America.

Latin America is expected to contribute 6.6% of the share in 2024, with a valuation of US$ 46 million. For the forecast period, the CAGR for Latin America is pegged to be an average of 5.8%. By 2034, Latin America is expected to account for 6.5% of the market share, and the valuation is expected to reach US$ 81 million.

What Makes the United States Such a Promising Country for the Cutaneous Fibrosis Treatment Market?

“High Rate of Approvals from the Food and Drug Administration (FDA) Allowing the Market to Grow by Leaps and Bounds in the United States”

The cutaneous fibrosis treatment market’s value in the United States for 2024 is anticipated to be US$ 201.0 million. The market is expected to register an encouraging CAGR of 6.1% in the United States from 2024 to 2034. By 2034, the market is projected to surpass a valuation of US$ 365 million. As newer drugs and treatments are introduced, manufacturers must rely on the FDA to approve their use and sale. Positively for the market, the FDA is helping the market to chug along with newer products by approving drugs and treatments consistently.

Why is the Cutaneous Fibrosis Treatment Market Experiencing High Demand in Mexico?

“Significant Rise in Medical Tourism Facilitating the Growth of the Market in Mexico”

The market value for Mexico in 2024 is marked at US$ 22.0 million and it is expected to register a promising CAGR of 6.6% over the forecast period, reaching a valuation of US$ 42.0 million in 2034.

Mexico is attracting several tourists for medical reasons. Mexico is advertising packages where medical treatment is included with traditional tourist activities. The presence of competent medical institutions also helps medical tourism in the country. For example, the city of Tijuana is home to specialized clinics that treat scleroderma and attracts several visitors from nearby American cities for the disease’s treatment. Thus, the market has expanded its scope in Mexico.

Category-wise Insights

The route of administration for cutaneous fibrosis treatment is most often oral, with an expected market share of 68.3% in 2024. Injectables come up behind oral in the route of administration segment, anticipated to account for 24.8% of the market share in 2024. Scleroderma is the top indication in the market, with an anticipated market share of 63.3% in 2024. Keloid takes the runner-up place, projected to contribute to 22.1% of the market share in 2024.

What Makes Scleroderma the Top Cause Necessitating Cutaneous Fibrosis Treatment?

“Worldwide Rise in Scleroderma Patients is Leading to More Use of Cutaneous Fibrosis Treatment”

Scleroderma is the disease whose occurrence most often predicts cutaneous fibrosis treatment. By 2024, scleroderma is anticipated to account for 68.3% of the market share. For the forecast period, the CAGR for the disease in the market is predicted to be 5.9%.

While the actual cause of scleroderma is unknown, its incidence is rising. As treatment options get better, people are less hesitant to take treatment for the disorder. Thus, scleroderma tops the indication segment of the market.

Competitive Landscape

The development of new products and forms of treatment is a priority for the market players. Companies are expanding the sales channels through which the treatment is being given to consumers. Thus, companies are bolstering their online presence.

The majority of the treatment sales depend on regulatory bodies approving the companies' new products. The inclination of regulatory bodies to support new drugs at a rapid pace is helping companies keep their product lines moving. Some of the key companies in the market are Novartis AG, Pfizer, Sanofi, F. Hoffmann La Roche (Genetech, Inc.), Boehringer Ingelheim International GmbH, Jubilant Cadista, Horizon Pharma USA, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals, Amgen, and Johnson & Johnson Services.

Some of the recent developments in the market are:

• In October 2023, Kyverna Therapeutics announced that the FDA had cleared the investigative use of KYV-101 to treat scleroderma.
• Also, in October 2023, Certa Therapeutics announced that its drug FT011 had received the organ drug designation from the FDA. The drug is intended for the treatment of scleroderma.
• In 2021, a trial was conducted on the effect of Rituximab on patients with systemic sclerosis, led by Ayumi Yoshizaki of the University of Tokyo. The effects of Rituximab were found to be positive.

Segmentation of Cutaneous Fibrosis Treatment Market Research

• By Drug Class:

  • Corticosteroids
  • Anti-fibrotic Drugs
  • Immunotherapy
  • Immunoglobulins

• By Route of Administration:

  • Oral
  • Injectable
  • Topical

• By Indication:

  • Keloid
  • Scleroderma
  • Radiation-induced Skin Fibrosis
  • GvHD Associated Cutaneous Fibrosis

• By Indication:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa